EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?

Simone Mosna, Dorothee Dormann

BioEssays · 2026-01 · 48 (1)

DOI: 10.1002/bies.70084 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioEssays, online erschienen am 02.11.2025. Verfasst von Simone Mosna und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Physiology, Faculty of Biology, Johannes Gutenberg University, Mainz, Germany. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Neurodegenerative Diseases, Protein Aggregation, Pathological. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (DFG), VERUM Foundation, Stiftung VERUM.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TDP‐43 is a ubiquitously expressed RNA‐binding protein that aggregates in the brains of patients suffering from neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Alzheimer's disease. Aggregated TDP‐43 in these diseases is hyperphosphorylated in its C‐terminal intrinsically disordered region, while physiological TDP‐43 is normally unphosphorylated. Whether TDP‐43 phosphorylation is a pathological driver, or rather a protective antagonist of TDP‐43 aggregation and consequently neurodegeneration, is still debated and a matter of ongoing research. Here, we review current knowledge about TDP‐43 phosphorylation in disease and the kinases and phosphatases that regulate this post‐translational modification. We discuss how TDP‐43 phosphorylation is thought to shape TDP‐43's phase separation, aggregation and toxicity in neurodegenerative diseases. We highlight recent research that provides evidence that hyperphosphorylation antagonizes TDP‐43 phase separation and aggregation, and speculate about a potential role of condensates in TDP‐43 phosphorylation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA-Binding ProteinsNeurodegenerative DiseasesProtein Aggregation, PathologicalHumansPhosphorylationProtein Processing, Post-TranslationalAmyotrophic Lateral SclerosisAnimalsFrontotemporal Dementia

Stichwörter der Autor:innen

TAR DNA binding protein of 43 kDa (TDP‐43)amyotrophic lateral sclerosis (ALS)condensatesfrontotemporal dementia (FTD)kinasesneurodegenerationphase separationphosphorylationprotein aggregation

Substanzen

DNA-Binding ProteinsTARDBP protein, human

Autor:innen und Institutionen

  • Institute of Molecular Physiology, Faculty of Biology, Johannes Gutenberg University, Mainz, Germany.
  • International PhD Programme (IPP) of IMB Mainz, Mainz, Germany.
  • Institute of Molecular Biology (IMB), Mainz, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft (DFG)
  • VERUM Foundation
  • Stiftung VERUM

Zitieren

APA

Mosna, S., & Dormann, D. (2026). TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?. BioEssays, 48(1). https://doi.org/10.1002/bies.70084

Vancouver

Mosna S, Dormann D. TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?. BioEssays. 2026;48(1). doi:10.1002/bies.70084

BibTeX
@article{Mosna2026,
  author = {Mosna, Simone and Dormann, Dorothee},
  title = {TDP‐43 Phosphorylation: Pathological Modification or Protective Factor Antagonizing TDP‐43 Aggregation in Neurodegenerative Diseases?},
  journal = {BioEssays},
  year = {2026},
  volume = {48},
  number = {1},
  doi = {10.1002/bies.70084}
}
Kostenlos starten →